Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock

TheMotleyFool

0 0

This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock: https://g.foolcdn.com/editorial/images/788380/three-doctors-and-three-nurses-discuss-a-readout-at-a-table.jpg

Novo Nordisk's (NYSE: NVO) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.

Here's what was just discovered and why it matters.

Source Fool.com

Like: 0

NVO

Share